AI assistant
Xlife Sciences AG — Delisting Announcement 2020
Jul 1, 2020
1041_dlst_2020-07-01_a5d23758-b763-4e16-a221-ef4131045622.html
Delisting Announcement
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
RNS Number : 6689R
Xlife Sciences AG
01 July 2020
Xlife Sciences AG: Xlife Sciences shares traded on XETRA
DGAP-Media / 01.07.2020
As of today, the shares of Xlife Sciences AG are traded in cooperation with the designated sponsor M.M.Warburg & CO on the electronic trading system XETRA of the Frankfurt Stock Exchange.
XETRA is by far the most important electronic trading venue in Germany with approximately 90% of all equity transactions in Germany occurring there. The ability to trade Xlife Sciences AG shares on XETRA will significantly increase trading volumes. Higher liquidity will result in tighter bid/ask spreads and orders will be able to be executed faster. The overall result will be more consistent and stable pricing.
Thus, Xlife Sciences AG continues focusing on the needs of its investors and further cultivates relationships with institutional investors
About Xlife Sciences AG
Xlife Sciences AG (m:access: XLS) is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage.
For more information, please visit: www.xlifesciences.ch
End of Media Release
Issuer: Xlife Sciences AG
Key word(s): Research/Technology
01.07.2020 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | Xlife Sciences AG |
| Klausstrasse 19 | |
| 8008 Zürich | |
| Switzerland | |
| Phone: | 0041 44 385 84 60 |
| E-mail: | [email protected] |
| Internet: | www.xlifesciences.ch |
| ISIN: | CH0461929603 |
| WKN: | A2PK6Z |
| Listed: | Regulated Unofficial Market in Munich |
| EQS News ID: | 1081909 |
| End of News | DGAP Media |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
NRAEFLBBBDLXBBQ